市場調査レポート

商品コード

1636768

乳がんスクリーニング検査市場の2030年までの予測：検査タイプ別、性別、エンドユーザー別、地域別の世界分析

Breast Cancer Screening Tests Market Forecasts to 2030 - Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography

出版日: 2025年01月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 597,849円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 756,315円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 914,781円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,080,450円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の乳がんスクリーニング検査市場は2024年に22億9,000万米ドルを占め、予測期間中にCAGR 9.8％で成長し、2030年には40億1,000万米ドルに達すると予測されています。

乳がんスクリーニング検査は、症状を示さない個人の乳がんの早期徴候を検出するために使用される医療処置です。主なスクリーニング方法には、マンモグラフィ、超音波、MRI、3Dマンモグラフィ（トモシンセシス）などがあります。これらの検査は、乳房組織の異常な増殖や変化を特定し、早期診断と治療を可能にすることを目的としています。定期的な検診は、特に乳がんのリスクが高い人において、より早期に、より治療可能な段階で腫瘍を発見することにより、生存率の向上に役立ちます。

European Breast Cancer Coalition 2023によると、乳がんは2023年に欧州で最も多く診断されるがんで、主に女性で約38万人が新たに罹患します。

早期発見への意識の高まり

早期発見に対する意識の高まりは、乳がんスクリーニング検査市場の拡大に不可欠です。がんを早期に発見することがいかに重要であるかを認識する個人が増えるにつれて、検診サービスに対する需要は劇的に増加しています。医療機関のキャンペーン、メディアの注目、教育活動により、早期発見が生命を救う利点が強調されています。このような知識の結果、検診プログラムへの参加は、特に高リスク群の間で増加しています。マンモグラフィ、MRI、超音波など数多くの検診法が幅広い層に利用されているのは、定期的な検診による早期発見が治療成績と生存率を向上させるという事実があるからです。

放射線被曝の懸念

放射線被曝に関する懸念は、乳がん検診技術の市場にとって大きな障害であり、特にマンモグラフィのような標準的な手技で低線量X線を使用する場合には大きな障害となります。マンモグラフィで使用される放射線は低線量であり、大多数の女性にとって安全であると考えられているが、長期間の被曝はがんリスクの上昇などの健康被害を引き起こす可能性があります。特に若い女性や家族歴のある女性にとっては、このような心配が頻繁に検診を受ける意欲を失わせることもあります。MRIや超音波のような放射線を使用しない代替検診法は、このような危険性を減らし、効率的な早期発見を保証するために、現在研究が進められています。

遺伝的危険因子に対する意識の高まり

遺伝的リスク、特にBRCA1およびBRCA2遺伝子の変異に関連するリスクに対する認識が高まり、早期スクリーニングや遺伝子検査を選択する人が増加しています。特に乳がんの家族歴がある女性は、このような意識から若いうちから定期的な検診を受けることが勧められています。遺伝子カウンセリングは、MRIやマンモグラフィのようなスクリーニング検査と組み合わせることで、リスクの高い患者を特定し、早期発見と積極的な監視を容易にします。より良いスクリーニング技術と遺伝子検査の必要性は、認識とともに高まっています。

熟練したヘルスケア専門家の不足

有資格の医療従事者、特に放射線科医や技師の不足は、乳がんスクリーニング検査市場における大きな障害です。マンモグラフィなどの検診データを正確に解釈するには高度な資格を持つ専門家が必要であり、彼らの不在は診断の遅れや検診効果の低下を招く。訓練を受けたスタッフの不足は、多くの地域、特に農村部や恵まれない地域でのタイムリーな検査へのアクセスを制限し、早期発見の取り組みに悪影響を及ぼします。ヘルスケア・システムはこの不足によってさらに負担を強いられており、教育イニシアティブや、医療従事者を支援するAIを活用した診断技術の創出に資金を提供する必要性が強調されています。

COVID-19の影響

COVID-19の大流行は乳がん検診市場を大きく混乱させました。多くのヘルスケア施設がCOVID-19の治療を優先するために定期検診を一時的に中止したためです。これは早期発見の遅れにつながり、患者の転帰に影響を及ぼす可能性があった。さらに、戸締まりやウイルスへの曝露の恐怖が、検診サービスを受けようとする個人の意欲を削いです。しかし、ヘルスケアシステムの適応に伴い、安全対策の実施、遠隔医療の利用の増加、早期診断のために遅れていたスクリーニングの再開に重点が置かれるなど、徐々に回復してきています。

予測期間中、画像検査分野が最大となる見込み

画像検査分野は、3Dマンモグラフィ、MRI、超音波などの診断技術の進歩に牽引され、最大規模になると推定されます。これらの画像検査は、より高い精度、腫瘍の早期発見、良性・悪性の鑑別を可能にします。さらに、乳がんの有病率の増加と早期発見に対する意識の高まりが画像検査の採用を後押ししています。技術革新、画像解像度の向上、人工知能の統合は、乳がん診断における画像診断の有効性をさらに高めています。

診断検査室セグメントは予測期間中最も高いCAGRが見込まれる

診断検査室分野は、マンモグラフィ、超音波、MRIのような先端技術を用いた専門的な診断サービスを提供することから、予測期間中に最も高いCAGRを記録すると予想されます。正確かつ早期の乳がん発見に対する需要の高まりが、診断ラボの成長を後押ししています。さらに、ヘルスケアインフラの改善や乳がん予防に対する意識の高まりも、患者数の増加に寄与しています。タイムリーで正確な診断結果を提供する検査施設の能力は、乳がんの早期発見と治療における重要性をさらに高めています。

最大のシェアを占める地域

アジア太平洋地域は、ヘルスケア意識の高まり、乳がん罹患率の増加、可処分所得の増加により、予測期間中最大の市場シェアを占めると予想されます。急速な都市化とヘルスケアインフラの改善により、検診サービスがより利用しやすくなっています。日本、中国、インドなどの国々では、政府の取り組みや検診プログラムが早期発見を促進しています。さらに、女性の健康に対する関心の高まりと診断技術の進歩が、この地域全体での乳がんスクリーニング検査の採用をさらに後押ししています。

CAGRが最も高い地域：

予測期間中、北米地域は最も高いCAGRを記録すると予測され、これは高いヘルスケア水準、強力な政府支援、先進医療技術などの要因に後押しされています。マンモグラフィやMRIなどの検診プログラムが広く普及しているため、早期発見と予防医療が奨励されています。乳がんに対する意識の高まりは、健康保険の適用範囲拡大と相まって、定期的な検診を促進しています。さらに、人口の高齢化、可処分所得の高さ、最先端の診断ツールへのアクセスが北米市場の成長に寄与しています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品発売
事業拡大
その他の主要戦略

第10章企業プロファイリング

GE Healthcare
Hologic, Inc.
Siemens Healthineers
Philips Healthcare
Canon Medical Systems Corporation
Koninklijke Philips N.V.
Fujifilm Holdings Corporation
IQM Diagnostics
Medtronic PLC
3M Health Care
Samsung Medison Co., Ltd.
Carestream Health, Inc.
Inovio Pharmaceuticals, Inc.
Volpara Health Technologies
Medimaps Group
Dilon Technologies, Inc.
LumaVision
Aurora Imaging Technology, Inc.

図表

List of Tables

Table 1 Global Breast Cancer Screening Tests Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
Table 3 Global Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
Table 4 Global Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
Table 5 Global Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
Table 6 Global Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
Table 7 Global Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
Table 8 Global Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
Table 9 Global Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
Table 10 Global Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
Table 11 Global Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
Table 12 Global Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
Table 13 Global Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
Table 14 Global Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
Table 15 Global Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
Table 16 Global Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
Table 17 Global Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
Table 18 Global Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
Table 19 Global Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
Table 20 Global Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
Table 21 Global Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
Table 22 Global Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
Table 23 Global Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
Table 24 Global Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
Table 25 North America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
Table 26 North America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
Table 27 North America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
Table 28 North America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
Table 29 North America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
Table 30 North America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
Table 31 North America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
Table 32 North America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
Table 33 North America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
Table 34 North America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
Table 35 North America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
Table 36 North America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
Table 37 North America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
Table 38 North America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
Table 39 North America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
Table 40 North America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
Table 41 North America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
Table 42 North America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
Table 43 North America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
Table 44 North America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
Table 45 North America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
Table 46 North America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
Table 47 North America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
Table 48 North America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
Table 49 Europe Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
Table 50 Europe Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
Table 51 Europe Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
Table 52 Europe Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
Table 53 Europe Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
Table 54 Europe Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
Table 55 Europe Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
Table 56 Europe Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
Table 57 Europe Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
Table 58 Europe Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
Table 59 Europe Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
Table 60 Europe Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
Table 61 Europe Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
Table 62 Europe Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
Table 63 Europe Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
Table 64 Europe Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
Table 65 Europe Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
Table 66 Europe Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
Table 67 Europe Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
Table 68 Europe Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
Table 69 Europe Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
Table 70 Europe Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
Table 71 Europe Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
Table 72 Europe Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
Table 73 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
Table 74 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
Table 75 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
Table 76 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
Table 77 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
Table 78 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
Table 79 Asia Pacific Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
Table 80 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
Table 81 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
Table 82 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
Table 83 Asia Pacific Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
Table 84 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
Table 85 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
Table 86 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
Table 87 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
Table 88 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
Table 89 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
Table 90 Asia Pacific Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
Table 91 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
Table 92 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
Table 93 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
Table 94 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
Table 95 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
Table 96 Asia Pacific Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
Table 97 South America Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
Table 98 South America Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
Table 99 South America Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
Table 100 South America Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
Table 101 South America Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
Table 102 South America Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
Table 103 South America Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
Table 104 South America Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
Table 105 South America Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
Table 106 South America Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
Table 107 South America Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
Table 108 South America Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
Table 109 South America Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
Table 110 South America Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
Table 111 South America Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
Table 112 South America Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
Table 113 South America Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
Table 114 South America Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
Table 115 South America Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
Table 116 South America Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
Table 117 South America Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
Table 118 South America Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
Table 119 South America Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
Table 120 South America Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)
Table 121 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Country (2022-2030) ($MN)
Table 122 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Test Type (2022-2030) ($MN)
Table 123 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Blood Tests (2022-2030) ($MN)
Table 124 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Imaging Test (2022-2030) ($MN)
Table 125 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Mammography (2022-2030) ($MN)
Table 126 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Magnetic Resonance Imaging (MRI) (2022-2030) ($MN)
Table 127 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By PET Scan (2022-2030) ($MN)
Table 128 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Ultrasound (2022-2030) ($MN)
Table 129 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Genetic Test (2022-2030) ($MN)
Table 130 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Fluorescence In Situ Hybridization (2022-2030) ($MN)
Table 131 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By HER gene test (2022-2030) ($MN)
Table 132 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Biopsy (2022-2030) ($MN)
Table 133 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Tomosynthesis (2022-2030) ($MN)
Table 134 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other Test Types (2022-2030) ($MN)
Table 135 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Gender (2022-2030) ($MN)
Table 136 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Male (2022-2030) ($MN)
Table 137 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Female (2022-2030) ($MN)
Table 138 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By End User (2022-2030) ($MN)
Table 139 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
Table 140 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Hospitals (2022-2030) ($MN)
Table 141 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Specialty Clinics (2022-2030) ($MN)
Table 142 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Cancer Institutes (2022-2030) ($MN)
Table 143 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Research Laboratories (2022-2030) ($MN)
Table 144 Middle East & Africa Breast Cancer Screening Tests Market Outlook, By Other End Users (2022-2030) ($MN)

Product Code: SMRC28410

According to Stratistics MRC, the Global Breast Cancer Screening Tests Market is accounted for $2.29 billion in 2024 and is expected to reach $4.01 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Breast cancer screening tests are medical procedures used to detect early signs of breast cancer in individuals who show no symptoms. The primary screening methods include mammography, ultrasound, MRI, and 3D mammography (tomosynthesis). These tests aim to identify abnormal growths or changes in breast tissue, allowing for early diagnosis and treatment. Regular screening helps improve survival rates by detecting tumours at an earlier, more treatable stage, especially in individuals at higher risk for breast cancer.

According to the European Breast Cancer Coalition 2023, breast cancer was the most commonly diagnosed cancer in Europe in 2023, with around 380,000 new cases, primarily among women.

Market Dynamics:

Driver:

Increasing awareness of early detection

Growing awareness of early detection is essential to the market expansion for breast cancer screening tests. Demand for screening services has increased dramatically as more individuals realize how important it is to detect cancer in its early stages. Health organizations' campaigning, media attention, and educational efforts have highlighted the life-saving advantages of early identification. Participation in screening programs has increased as a result of this knowledge, particularly among high-risk groups. Numerous screening techniques, including mammography, MRI, and ultrasound, are being used by a wide range of demographics due to the fact that early identification through routine screening improves treatment results and survival rates.

Restraint:

Radiation exposure concerns

Concerns about radiation exposure present a major obstacle to the market for breast cancer screening technologies, especially when using low-dose X-rays in standard procedures like mammography. Even while the radiation used in mammograms is considered to be low and safe for the majority of women, prolonged exposure might cause health hazards, such as an elevated risk of cancer. Particularly for younger women or those with a family history of cancer, these worries may discourage some people from getting frequent checkups. Alternative, non-radiative screening techniques like MRI and ultrasound are now being investigated in an effort to lower these hazards and guarantee efficient early identification.

Opportunity:

Rising awareness of genetic risk factors

Growing awareness of genetic risks, especially those associated with mutations in the BRCA1 and BRCA2 genes, has led to an increase in the number of people choosing early screening and genetic testing. Women are encouraged to get regular screenings at a younger age because of this awareness, particularly those who have a family history of breast cancer. When paired with screening procedures like MRIs and mammograms, genetic counseling assists in identifying high-risk patients, facilitating early detection and proactive monitoring. The need for better screening techniques and genetic testing is increasing along with awareness.

Threat:

Shortage of skilled healthcare professionals

The lack of qualified medical personnel, especially radiologists and technicians, is a major obstacle in the market for breast cancer screening testing. It takes highly qualified specialists to accurately interpret screening data, such mammograms, and their absence can cause delays in diagnosis and decreased screening efficacy. The lack of trained staff restricts access to timely tests in many areas, particularly in rural or underprivileged areas, which has a detrimental effect on early detection initiatives. Healthcare systems are further burdened by this scarcity, underscoring the necessity of funding educational initiatives and the creation of AI-powered diagnostic technologies to assist medical practitioners.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the breast cancer screening tests market, as many healthcare facilities temporarily suspended routine screenings to prioritize COVID-19 care. This led to delays in early detection, potentially affecting patient outcomes. Additionally, lockdowns and fear of exposure to the virus discouraged individuals from seeking screening services. However, as healthcare systems adapt, there has been a gradual recovery with the implementation of safety measures, increased use of telemedicine, and a focus on resuming delayed screenings for early diagnosis.

The imaging test segment is expected to be the largest during the forecast period

The imaging test segment is estimated to be the largest, driven by advancements in diagnostic technologies, such as 3D mammography, MRI, and ultrasound. These imaging tests provide higher accuracy, early detection of tumours, and better differentiation between benign and malignant growths. Additionally, the increasing prevalence of breast cancer, along with rising awareness of early detection, fuels the adoption of imaging tests. Technological innovations, improved image resolution, and integration of artificial intelligence further enhance the effectiveness of imaging in breast cancer diagnosis.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is anticipated to witness the highest CAGR during the forecast period, as they provide specialized diagnostic services using advanced technologies like mammography, ultrasound, and MRI. The increasing demand for accurate and early breast cancer detection fuels growth in diagnostic labs. Additionally, improved healthcare infrastructure and rising awareness of breast cancer prevention contribute to higher patient volumes. Laboratories' ability to offer timely and precise diagnostic results further enhances their importance in the early detection and treatment of breast cancer.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to growing healthcare awareness, increasing breast cancer prevalence, and rising disposable incomes. Rapid urbanization and improvements in healthcare infrastructure are making screening services more accessible. Government initiatives and screening programs in countries like Japan, China, and India are promoting early detection. Additionally, a rising focus on women's health, coupled with advancements in diagnostic technologies, further boosts the adoption of breast cancer screening tests across the region.

Region with highest CAGR:

During the forecast period, the North America region is anticipated to register the highest CAGR, fueled by factors such as high healthcare standards, strong government support, and advanced medical technologies. The widespread availability of screening programs, including mammography and MRI, encourages early detection and preventive care. Rising awareness about breast cancer, coupled with increased health insurance coverage, promotes regular screenings. Additionally, the aging population, high disposable incomes, and access to cutting-edge diagnostic tools further contribute to the market's growth in North America.

Key players in the market

Some of the key players profiled in the Breast Cancer Screening Tests Market include GE Healthcare, Hologic, Inc., Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Koninklijke Philips N.V., Fujifilm Holdings Corporation, IQM Diagnostics, Medtronic PLC, 3M Health Care, Samsung Medison Co., Ltd., Carestream Health, Inc., Inovio Pharmaceuticals, Inc., Volpara Health Technologies, Medimaps Group, Dilon Technologies, Inc., LumaVision, and Aurora Imaging Technology, Inc.

Key Developments:

In March 2024, Philips strengthens strategic partnership with Sim&Cure to expand innovation in neurovascular therapy. Philips announced the expansion of its strategic partnership with Sim&Cure, a leading provider of advanced digital solutions for neurovascular therapy. The partnership between the two companies started 5 years ago.

In May 2024, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, announced it has signed an agreement to acquire 100% of the shares of Sonio SAS, a fetal ultrasound AI software company.

In March 2024, GE Healthcare Wipro, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, today announced an investment of over INR8000 Crores in manufacturing output & local R&D over next 5 years.

Test Types Covered:

Blood Tests
Imaging Test
Genetic Test
Biopsy
Tomosynthesis
Other Test Types

Genders Covered:

Male
Female

End Users Covered:

Diagnostic Laboratories
Hospitals
Specialty Clinics
Cancer Institutes
Research Laboratories
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Breast Cancer Screening Tests Market, By Test Type

5.1 Introduction
5.2 Blood Tests
5.3 Imaging Test
- 5.3.1 Mammography
- 5.3.2 Magnetic Resonance Imaging (MRI)
- 5.3.3 PET Scan
- 5.3.4 Ultrasound
5.4 Genetic Test
- 5.4.1 Fluorescence In Situ Hybridization
- 5.4.2 HER gene test
5.5 Biopsy
5.6 Tomosynthesis
5.7 Other Test Types

6 Global Breast Cancer Screening Tests Market, By Gender

6.1 Introduction
6.2 Male
6.3 Female

7 Global Breast Cancer Screening Tests Market, By End User

7.1 Introduction
7.2 Diagnostic Laboratories
7.3 Hospitals
7.4 Specialty Clinics
7.5 Cancer Institutes
7.6 Research Laboratories
7.7 Other End Users

8 Global Breast Cancer Screening Tests Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 GE Healthcare
10.2 Hologic, Inc.
10.3 Siemens Healthineers
10.4 Philips Healthcare
10.5 Canon Medical Systems Corporation
10.6 Koninklijke Philips N.V.
10.7 Fujifilm Holdings Corporation
10.8 IQM Diagnostics
10.9 Medtronic PLC
10.10 3M Health Care
10.11 Samsung Medison Co., Ltd.
10.12 Carestream Health, Inc.
10.13 Inovio Pharmaceuticals, Inc.
10.14 Volpara Health Technologies
10.15 Medimaps Group
10.16 Dilon Technologies, Inc.
10.17 LumaVision
10.18 Aurora Imaging Technology, Inc.

乳がんスクリーニング検査市場の2030年までの予測：検査タイプ別、性別、エンドユーザー別、地域別の世界分析

Breast Cancer Screening Tests Market Forecasts to 2030 - Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界の乳がんスクリーニング検査市場：検査タイプ別

第6章 世界の乳がんスクリーニング検査市場：性別

第7章 世界の乳がんスクリーニング検査市場：エンドユーザー別

第8章 世界の乳がんスクリーニング検査市場：地域別

第9章 主な発展

第10章 企業プロファイリング